Australia’s first oral GLP-1 weight-loss medication hit pharmacy shelves on Friday after the Therapeutic Goods Administration approved Novo Nordisk’s Wegovy tablets this month, with a second pill, Eli Lilly’s Foundayo, also cleared for use, SBS News reported.
How the tablets work
Both Wegovy and Foundayo mimic glucagon-like peptide-1, a gut hormone that regulates blood sugar and appetite. Wegovy contains semaglutide; the TGA registered four strengths — 1.5 mg, 4 mg, 9 mg and 25 mg — specifically for chronic weight management, the ABC reported. A 25 mg tablet delivers roughly the same effect as a 2.4 mg weekly injection because oral absorption is less efficient, the ABC noted.
Daily pill versus weekly injection
The Wegovy tablet must be taken on an empty stomach with water, followed by a 30-minute wait before eating or drinking anything else. The injection can be given any time, with or without food, once a week. Foundayo differs again: it can be taken at any time of day without the same fasting restrictions, Professor Priya Sumithran, head of the obesity and metabolic medicine group at Monash University, told SBS News.
Weight-loss outcomes are similar. Trials showed about 14 per cent body-weight loss over 64–68 weeks for the tablet versus 15 per cent for the injection, the ABC reported. Side-effect profiles also match — nausea, vomiting, diarrhoea and constipation affect roughly 80 per cent of patients starting either format, the ABC said. Serious but rarer risks include kidney injury, pancreatitis and gallbladder problems.
“I think the considerations would mostly be up to personal preference — whether you prefer to take a once-a-week injection, [or] whether you prefer to take a once-a-day tablet,” Professor Priya Sumithran, head of the obesity and metabolic medicine group at Monash University, told SBS News.
Wegovy tablets only on private prescription
Wegovy tablets are available on private prescription in Australia, SBS News reported. The drug is not listed on the Pharmaceutical Benefits Scheme, though the Pharmaceutical Benefits Advisory Committee recommended it nearly a year ago. Federal negotiations with Novo Nordisk continue for a limited PBS listing that would lower the price to $25 per script or $7.70 for concession card holders, SBS News said.
“It’s only available on private prescription. Until obesity medicines are subsidised, access will be determined by what people can afford rather than by clinical need,” said Dr Terri-Lynne South, a GP with a special interest in obesity management at the Royal Australian College of General Practitioners, speaking to SBS News.
Who is eligible
Adults with a body mass index of 30 or higher, or a BMI of 27–30 with at least one weight-related comorbidity such as knee osteoarthritis or fatty liver, qualify for a prescription, The Guardian reported. The indication also covers cardiovascular risk reduction in certain patients.
“have lived up to and exceeded the hype,” Dr Brendan Hanrahan, an obesity medicine expert at Brisbane's Wesley hospital, said.

Surge in GLP-1 use documented in Australian data
Sales of Wegovy, Ozempic and other GLP-1 drugs for diabetes increased almost tenfold between May 2020 and April 2025, according to University of New South Wales research cited by SBS News. At least half a million people are estimated to be regularly using the medications in Australia.
Kim Roberts, a teacher and mother of six, has used weekly injections for three years after a heart attack revealed a genetic cholesterol condition. She told AAP she plans to switch to the daily Wegovy tablet, saying “it will just fit in with what I do on a day-to-day basis” and that the drug has helped her lose around 30 kilograms.
TGA confirms four approved strengths
A TGA spokesperson confirmed the four approved strengths to the ABC.
Novo Nordisk previously flagged Australia as a priority market after three million prescriptions in the pill’s first five months in the US.
Australia’s Pharmaceutical Benefits Scheme (PBS) subsidises medicines recommended by the Pharmaceutical Benefits Advisory Committee (PBAC), but PBS listing requires a separate pricing agreement between the Federal Government and the manufacturer. The PBAC recommended Wegovy for a limited PBS listing nearly a year ago, yet Federal negotiations with Novo Nordisk continue, leaving the drug available only on private prescription, SBS News reported.
What comes next
Nearly 30 new obesity medications are in late-stage trials, many combining GLP-1 with other hormones to improve efficacy or target specific conditions, Professor Sumithran told SBS News. Researchers are also studying GLP-1 use in children; a recent trial tested injectable semaglutide in children aged six to 12, Professor Louise Baur of the University of Sydney told SBS News.
“Obesity is a chronic disease, and weight regain is common when treatment stops, so it is important to discuss the long-term plan with patients, including cost, before starting,” Dr South told SBS News.